Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET-scan method may sharpen brachytherapy for cervical cancer

NCT ID NCT03315351

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether using a PET-scan at the start of brachytherapy (internal radiation) is feasible for patients with locally advanced cervical cancer. Fourteen participants who have already received chemoradiation will undergo an extra PET-scan during brachytherapy and another four months later. The goal is to see if this approach helps doctors better define the tumor target for treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more precise brachytherapy for cervical cancer, potentially improving tumor targeting and reducing side effects.
What could go wrong
This is a very small, early feasibility study with only 14 participants. It does not test whether the approach actually improves outcomes, so it may not lead to any practical change in treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Nov 2017

Finished

Mar 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient suffering from a cervical cancer: * squamous-cell carcinoma or adenocarcinoma histologically proven * classified from FIGO 2009 IB2 to IVA stage * Age ≥ 18 years old * Examination by PET-scan and pelvic RMI realized at diagnosis * Examination by negative PET-scan remotely closed and at lymph node level * Surgical lymphadenectomy negative at paraaortic level * Treatment by external radiotherapy (doses between 45 Gy and 50.4 Gy in 1.8 Gy/fractions) and concomitant chemotherapy (at least 4 cures per weeks using platinum salt) done * Scheduled curative treatment by brachytherapy driven by RMI * Affiliation to the National Social Security System * With informed and signed consent before any procedure specific to the study Exclusion Criteria: * Performance status of WHO score \> 2 * Other histology than squamous cell carcinoma or adenocarcinoma * Metastatic patient or paraaortic node positive * Adjuvant radiochemotherapy after the first surgery * Dementia or psychiatric history * Kidney failure * Diabet * Chronic inflammatory bowel disease * Pelvic and/or vesicoureteral surgery history * Pelvic irradiation history * Other active neoplasia or \< 5 years old, except for basocellular carcinoma that can be locally treated * Contraindication to one of the following procedure : RMI, PET-scan, general anesthesia * Radiosensitive disease (Fragile X syndrome, Huntington's chorea, Xeroderma Pigmentosum, connective tissue disease) or signs of radiosensitivity. * Treatment with palliative intent * Pregnant or breastfeeding women * Patient Under guardianship or tutorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.